As a result, Novo Nordisk and Eli Lillys historical dominance will face its first real structural challenge, not from USA or European biotech startups, but from Indian and Chinese players scaling biosimilars and new molecular entities for export
Who Benefits Most from Microdosing GLP-1
If you accidentally leave a reconstituted vial out overnight, it may still be usable, but potency loss is almost certain
compounding pharmacies
If you need or are considering prescription GLP-1 therapy, that conversation belongs with a licensed healthcare provider, not a supplement purchase
Right now, the key questions are about investigational status, supervised access routes, and how to judge risk versus cost